Connection domain mutations in treatment-experienced patients in the OPTIMA trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 2, 2010, Pages 160-166

  Dau, Birgitt ^a   Ayers, Dieter ^b   Singer, Joel ^b   Harrigan, P Richard ^c   Brown, Sheldon ^d   Kyriakides, Tassos ^e   Cameron, D William ^f   Angus, Brian ^g   Holodniy, Mark ^a,h  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b Canadian HIV Trials Network   (Canada)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VA Cooperative Studies Program Coordinating Center   (United States)

^f UNIVERSITY OF OTTAWA   (Canada)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral; Clinical trial; HIV; Resistance; Veterans

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MUTATION RATE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNIVARIATE ANALYSIS; VIRUS LOAD; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE;

EID: 77953059719     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181cbd235     Document Type: Article

References (28)

1. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'- deoxythymidine resistance. Proc Natl Acad Sci U S A. 2007;104: 317-322.
2. Yap SH, Sheen CW, Fahey J, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007;4:e335.
3. Ehteshami M, Beilhartz GL, Scarth BJ, et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem. 2008;283: 22222-22232.
4. Kohlstaedt LA, Wang J, Friedman JM, et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256:1783-1790.
5. Gotte M. Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing. PLoS Med. 2007;4:e346.
6. Schultz SJ, Champoux JJ. RNase H activity: structure, specificity, and function in reverse transcription. Virus Res. 2008;134:86-103.
7. Julias JG, McWilliams MJ, Sarafianos SG, et al. Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. J Virol. 2003;77:8548-8554.
8. El Safadi Y, Vivet-Boudou V, Marquet R. HIV-1 reverse transcriptase inhibitors. Appl Microbiol Biotechnol. 2007;75:723-737.
9. Arion D, Kaushik N, McCormick S, et al. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry. 1998;37: 15908-15917.
10. Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry. 2008;47:14020-14027.
11. Nikolenko GN, Palmer S, Maldarelli F, et al. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A. 2005;102: 2093-2098.
12. Delviks-Frankenberry KA, Nikolenko GN, Barr R, et al. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'- deoxythymidine resistance. J Virol. 2007;81:6837-6845.
13. Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, et al. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci U S A. 2008; 105:10943-10948.
14. Brehm JH, Koontz D, Meteer JD, et al. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideox-ythymidine. J Virol. 2007;81:7852-7859.
15. Figueiredo A, Tyssen D, Kuiper M, et al. The E399G mutation in the connection domain of the HIV-1 reverse transcriptase potentiates resistance to efavirenz. Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention incorporating the 19th ASHM Conference. July 22-25, 2007, Sydney, Australia. Abstract MOPEA060.
16. Harrigan PR, Salim M, Stammers DK, et al. A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol. 2002;76:6836-6840.
17. Kemp SD, Shi C, Bloor S, et al. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol. 1998;72:5093-5098.
18. Santos AF, Lengruber RB, Soares EA, et al. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS ONE. 2008;3:e1781.
19. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16:62-68.
20. Kyriakides TC, Babiker A, Singer J, et al. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom ART has failed: rationale and design of the OPTIMATrial. Control Clin Trials. 2003;24:481-500.
21. Brown S, and The OPTIMA Study Team. Clinical outcomes from OPTIMA: a randomized controlled trial of antiretroviral treatment interruption or intensification in advance multi-drug resistant HIV infection. Presented at: AIDS 2008 - XVII International AIDS Conference, August 3-8, 2008, Mexico City, Mexico. Abstract no. LBPE1145.
22. Winters B, Montaner J, Harrigan PR, et al. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J Acquir Immune Defic Syndr. 2008;48:26-34.
23. Winters B, Van Craenenbroeck E, Van der Borght K, et al. Clinical cutoffs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J Virol Methods. 2009;162:101-108.
24. Virco. Clinical Cut-offs. Available at: http://www.vircolab.com/hiv- resistance-products/vircotype-hiv-1/cut-offs-for-vircotype-hiv-1/ clinicalcut-offs. Accessed June 1, 2009.
25. Stanford University HIV Drug Resistance Database. Available at: http:// hivdb.stanford.edu. Accessed February 25, 2009.
26. Holodniy M, Singer J, Ayers D, et al. Baseline Antiretroviral Resistance Profile and Correlation with Clinical Events in the OPTIMA Trial. Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract TUPEB044.
27. Gianotti N, Galli L, Boeri E, et al. The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2006;41:447-452.
28. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2008;16:138-145.